# LENZ — LENZ Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** LENZ  
**Sources:** 17  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-lenz-lenz-therapeutics-inc-catalysts-narrative-risks-10508

---

# LENZ Therapeutics, Inc. (Nasdaq: LENZ) — Point-in-Time Research (as of 2026-11-01)

## Background
LENZ Therapeutics is a San Diego, California–headquartered commercial pharmaceutical company focused on developing and commercializing ophthalmic therapies for presbyopia (age-related loss of near vision) in the United States. Its flagship product is VIZZ® (aceclidine ophthalmic solution) 1.44%, described as the first and only FDA-approved aceclidine-based eye drop for presbyopia. The company was formerly Presbyopia Therapies, Inc. [[14]](https://www.marketbeat.com/stocks/NASDAQ/LENZ/), [[18]](https://stockanalysis.com/stocks/lenz/), [[20]](https://lenz-tx.com/). As of late October 2026, it carried a market capitalization of approximately $95.83 million, with a stock price near $3.05 and roughly 31.4 million shares outstanding [[13]](https://ir.lenz-tx.com/news-events/press-releases), [[14]](https://www.marketbeat.com/stocks/NASDAQ/LENZ/), [[16]](https://stockanalysis.com/stocks/lenz/forecast/), [[17]](https://finance.yahoo.com/quote/LENZ/), [[18]](https://stockanalysis.com/stocks/lenz/).

## Recent Catalysts (roughly July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-lenz-lenz-therapeutics-inc-catalysts-narrative-risks-10508 (free to sign up)._